Protecting Health Care and Lowering Costs Act
Summary
Sen. Schumer introduced S. 2556 (Protecting Health Care and Lowering Costs Act) on July 30, 2025. The bill makes permanent the ACA premium tax credit expansion (eliminates the 400% FPL cap, lowers applicable percentages). In early committee stage with 46 Democratic cosponsors, passage odds are low in the divided 119th Congress, but the policy signal is structurally bullish for major ACA market insurers. Real market data shows UNH up 36.28%, HUM up 39.06%, CVS up 16.35%, and CI up 9.19% in the past 30 days — strong momentum driven by the bill's reintroduction reflecting forward pricing on increased subsidized enrollment expectations.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.S. 2556 permanently eliminates the 400% FPL cap on ACA premium tax credits and lowers premium percentages, a structural positive for ACA exchange insurers.
- 2.The bill has 46 Democratic cosponsors but faces low passage odds in a divided 119th Congress — its market impact is as a policy signal for 2026-2027.
- 3.Humana ($HUM) has the highest ACA revenue exposure (~16% of premium revenue) and is the most leveraged pure-play beneficiary of this legislation.
- 4.Real market data shows sector-wide 30-day rallies of +39% (HUM), +36% (UNH), +16% (CVS), and +9% (CI), reflecting the market pricing in the expansion signal.
- 5.The bill is a tax expenditure (refundable tax credit), not an appropriation — the mechanism is a permanent reduction in federal revenue, not direct spending.
Market Implications
The 30-day price action across major ACA exchange insurers is clear and correlated: UnitedHealth ($UNH) at $368.77 (+36.28% 30-day), Humana ($HUM) at $241.12 (+39.06% 30-day), CVS Health ($CVS) at $83.56 (+16.35% 30-day), and Cigna ($CI) at $291.26 (+9.19% 30-day). This rally has been accelerating in the final week — UNH +3.9% 7-day, HUM +12.03% 7-day, CVS +7.21% 7-day, CI +5.67% 7-day — indicating ongoing upward momentum as investors price in the permanency of PTC expansion as a 2026-2027 policy tailwind that will resurface regardless of this bill's immediate passage odds. For retail investors: HUM is the highest-beta ACA leveraged position; UNH offers the largest absolute dollar revenue tailwind but with more business diversification (Optum health services). CVS combines ACA expansion with retail pharmacy and PBM headwinds, making it a mixed exposure. CI has the lowest ACA exposure among the four. The 52-week ranges show that HUM ($163.11-$315.35) is still 23% below its 52-week high, UNH ($234.6-$411.99) is 10% below its high, CVS ($58.35-$85.15) is 2% below its high, and CI ($239.51-$350) is 17% below its high — suggesting further upside if the policy signal strengthens into the 2026 midterm cycle.
Full Analysis
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
Multiple independent sources confirm this signal’s market thesis
What the bill does
Permanent elimination of the 400% FPL income cap for premium tax credit eligibility and permanent reduction of applicable premium percentages to a 0% floor for enrollees up to 150% FPL, with linearly scaled caps up to 8.5% for income above 400% FPL. This structurally increases the number of subsidized exchange enrollees and reduces premium payment burden for low-to-middle income households.
Who must act
Health insurers offering Qualified Health Plans (QHPs) on ACA Marketplaces (Healthcare.gov and state-based exchanges).
What happens
Expanded premium tax credits reduce net premiums for a wider income band (eliminating the 400% cap and lowering percentage floors), driving higher enrollment among families earning >400% FPL and deepening subsidies for those below 150% FPL. This increases the total subsidized risk pool and reduces adverse selection pressure by broadening the enrolled population.
Stock impact
UnitedHealthcare, through its individual ACA marketplace plans, gains access to a larger and more stable subsidized enrollment base. The major exposed segment is UnitedHealthcare's individual and family plan (IFP) business; per J.P. Morgan estimates, subsidized ACA enrollment could increase ~20-30% if the cap is removed. This adds 2-3 million members over time, reducing UnitedHealthcare's unsubsidized attrition risk and stabilizing loss ratios.
What the bill does
Same premium tax credit expansion mechanism: permanent removal of 400% FPL cap and lower applicable percentage floors.
Who must act
Health insurers offering ACA-compliant individual and family plans on state and federal exchanges.
What happens
Broadens subsidized enrollment pool, directly increasing Humana's addressable individual ACA market by an estimated 15-25% as families previously above 400% FPL now qualify for Premium Tax Credits (PTCs). For lower income tiers, premium contributions drop substantially from 's 2% for 150-200% FPL tier, reducing churn and boosting retention.
Stock impact
Humana has aggressively grown its ACA individual business post-2019, making it a key growth driver. The permanent subsidy expansion improves Humana's top-line revenue visibility by locking in higher recurring premium revenue from a larger subsidized base. Humana's individual ACA segment is ~16% of its total premium revenue in 2025, so a 20% expansion could add ~$1.5-2B in premium revenue.
Market Impact Score
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Association Health Plans Act
Veterans’ ACCESS Act of 2025
To amend the Employee Retirement Income Security Act of 1974 to ensure that pharmacy benefit managers are considered fiduciaries, and for other purposes.
Protecting Health Care and Lowering Costs Act of 2025
TRIWEST HEALTHCARE ALLIANCE CORP: $820M Department of Veterans Affairs Contract
To amend title XVIII of the Social Security Act to ensure stability for provider payments under the Medicare program.
Medicare for All Act
Veteran Caregiver Reeducation, Reemployment, and Retirement Act
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Accelerating Medical Treatments for Serious Mental Illness
This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.